Zhejiang Hisoar Pharmaceutical Hits Day Low Amid Price Pressure at CNY 5.22

Zhejiang Hisoar Pharmaceutical Co., Ltd. has experienced a notable decline today, with the stock dropping by 5.02% as of June 8, 2026. The stock reached an intraday low of CNY 5.22, reflecting ongoing challenges in its market performance. Over the past week, the company has seen a significant decrease of 12.69%, while its performance over the past month has declined by 13.11%. In a broader context, the stock has underperformed against the China Shanghai Composite index, which has only fallen by 2.43% in the same week and 5.28% over the month. Year-to-date, Zhejiang Hisoar's performance stands at a loss of 15.06%, contrasting sharply with the slight decline of 0.24% in the benchmark index. The company's long-term growth prospects appear weak, with net sales decreasing at an annual rate of 5.79% over the last five years. Additionally, the Return on Capital Employed (ROCE) is notably low at 2.16%, indicating challenges in generating profitability from its capital investments. As a mid-cap player in the pharmaceuticals and biotechnology sector, Zhejiang Hisoar continues to face significant hurdles in its operational efficiency and market positioning.